Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Idera to present data from Phase 2 trial of IMO-3100 in patients with psoriasis at IID 2013

Idera Pharmaceuticals today announced presentation of data from its randomized, double-blind, placebo-controlled Phase 2 trial that showed improvements from baseline of up to 90% in Psoriasis Area Severity Index scores in patients with moderate to severe plaque psoriasis following four weeks of treatment with the Toll-like Receptor antagonist IMO-3100.

8 May 2013

BioMed Central launches new journal Acta Neuropathologica Communications

Open access publisher BioMed Central is proud to announce the launch of Acta Neuropathologica Communications (ANC). ANC will publish work on pathology and mechanisms of neurological disease using structural, molecular and cellular techniques.

8 May 2013

Taking strong anticholinergic doubles risk of developing cognitive impairment in older adults

Research from the Regenstrief Institute, the Indiana University Center for Aging Research and Wishard-Eskenazi Health on medications commonly taken by older adults has found that drugs with strong anticholinergic effects cause cognitive impairment when taken continuously for as few as 60 days.

8 May 2013

Scientists discover how Alzheimer's pharmaceuticals sharpen the brain's performance

Scientists at the Virginia Tech Carilion Research Institute have discovered how the predominant class of Alzheimer's pharmaceuticals might sharpen the brain's performance.

8 May 2013

Immunoglobulin fails to meet co-primary endpoints in Phase III clinical study, Baxter reports

Baxter International Inc. today announced that its Phase III clinical study of immunoglobulin did not meet its co-primary endpoints of reducing cognitive decline and preserving functional abilities in patients with mild to moderate Alzheimer's disease.

From Baxter International Inc. 8 May 2013

New gene implicated in Parkinson can delay onset of aging, extend life span

UCLA life scientists have identified a gene previously implicated in Parkinson's disease that can delay the onset of aging and extend the healthy life span of fruit flies. The research, they say, could have important implications for aging and disease in humans.

7 May 2013

Anavex invited to submit funding application for Phase 2a trial of ANAVEX 2-73

Anavex Life Sciences Corp. ("Anavex") (OTCQB: AVXL) today announced that it has been invited to submit a full grant application to the Alzheimer's Drug Discovery Foundation ("ADDF") for a Phase 2a trial of ANAVEX 2-73.

7 May 2013

Targacept reports net loss of $8.1 million in first quarter 2013

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today reported its financial results for the first quarter ended March 31, 2013.

7 May 2013

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Kinase inhibitors are molecules that block the activity of kinases. Kinases are a specific class of enzymes. They are extremely important in signal transduction processes in the human body meaning that they actually regulate most of the physiological processes that take place in the body.

7 May 2013

Study examines link between families with exceptional longevity and cognitive impairment

A study by Stephanie Cosentino, Ph.D., of Columbia University, New York, and colleagues examines the relationship between families with exceptional longevity and cognitive impairment consistent with Alzheimer disease.

7 May 2013

NeuroPhage Pharmaceuticals raises $6.4 million in private equity financing round

NeuroPhage Pharmaceuticals, Inc., a company developing breakthrough therapies for neurodegenerative diseases, today announced that it raised $6.4 million in a private equity financing round.

6 May 2013

Discovery may lead to new treatment for neurodevelopmental, neurodegenerative disorders

A key type of human brain cell developed in the laboratory grows seamlessly when transplanted into the brains of mice, UC San Francisco researchers have discovered, raising hope that these cells might one day be used to treat people with Parkinson's disease, epilepsy, and possibly even Alzheimer's disease, as well as and complications of spinal cord injury such as chronic pain and spasticity.

5 May 2013

Virtual reality reveals new clues on how cells determine place

Leaving the house in the morning may seem simple, but with every move we make, our brains are working feverishly to create maps of the outside world that allow us to navigate and to remember where we are.

4 May 2013

Receiving general anesthesia not associated with dementia in elderly patients, research finds

Elderly patients who receive anesthesia are no more likely to develop long-term dementia or Alzheimer's disease than other seniors, according to new Mayo Clinic research.

2 May 2013

UCSF study focuses on vexing problems of handling skin cancers among elderly patients

Surgery is often recommended for skin cancers, but older, sicker patients can endure complications as a result and may not live long enough to benefit from the treatment.

30 Apr 2013

Researchers identify how a defective protein plays central role in Giant Axonal Neuropathy

A team of international researchers led by Northwestern Medicine scientists has identified how a defective protein plays a central role in a rare, lethal childhood disease known as Giant Axonal Neuropathy, or GAN.

29 Apr 2013

Revised criteria improve early-onset dementia diagnosis

Updated diagnostic criteria based on the Frontotemporal Dementia Consensus are “encouragingly” sensitive and specific in identifying patients who have early-onset dementia, a study finds.

29 Apr 2013

Opsona raises €33M in oversubscribed financing round

Opsona Therapeutics Limited, the innate immune drug development company, today announced that it has raised €33 million (US $ 43 million) in an oversubscribed Series C financing.

29 Apr 2013

UK’s health performance: an interview with Prof. Murray, University of Washington

Rates of premature mortality in the UK have been falling steadily, but the pace of decline is not as fast as in many other high-income countries, such as Australia. In that sense, the UK lags behind.

29 Apr 2013

Intermittent fasting: A path to weight loss and improved cardiovascular risk

Intermittent fasting is all the rage, but scientific evidence showing how such regimes affect human health is not always clear cut. Now a scientific review in the British Journal of Diabetes and Vascular Disease published by SAGE, suggests that fasting diets may help those with diabetes and cardiovascular disease, alongside established weight loss claims.

29 Apr 2013

Alzheimer's Disease News and Research

Further Reading

Idera to present data from Phase 2 trial of IMO-3100 in patients with psoriasis at IID 2013

BioMed Central launches new journal Acta Neuropathologica Communications

Taking strong anticholinergic doubles risk of developing cognitive impairment in older adults

Scientists discover how Alzheimer's pharmaceuticals sharpen the brain's performance

Immunoglobulin fails to meet co-primary endpoints in Phase III clinical study, Baxter reports

New gene implicated in Parkinson can delay onset of aging, extend life span

Anavex invited to submit funding application for Phase 2a trial of ANAVEX 2-73

Targacept reports net loss of $8.1 million in first quarter 2013

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Study examines link between families with exceptional longevity and cognitive impairment

NeuroPhage Pharmaceuticals raises $6.4 million in private equity financing round

Discovery may lead to new treatment for neurodevelopmental, neurodegenerative disorders

Virtual reality reveals new clues on how cells determine place

Receiving general anesthesia not associated with dementia in elderly patients, research finds

UCSF study focuses on vexing problems of handling skin cancers among elderly patients

Researchers identify how a defective protein plays central role in Giant Axonal Neuropathy

Revised criteria improve early-onset dementia diagnosis

Opsona raises €33M in oversubscribed financing round

UK’s health performance: an interview with Prof. Murray, University of Washington

Intermittent fasting: A path to weight loss and improved cardiovascular risk

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News